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Despite clinical studies indicating that diabetic hearts are more sensitive to ischemia/reperfusion injury, experimental data is
contradictory. Although mild diabetes prior to ischemia/reperfusion may induce a myocardial adaptation, further research is still
needed. Nondiabetic Wistar (W) and type 2 diabetic Goto-Kakizaki (GK) rats (16-week-old) underwent 45min occlusion of the
left anterior descending coronary artery and 24 h reperfusion. The plasma glucose level was significantly higher in diabetic rats
compared to the nondiabetics. Diabetes mellitus was associated with ventricular hypertrophy and increased interstitial fibrosis.
Inducing myocardial infarction increased the glucose levels in diabetic compared to nondiabetic rats. Furthermore, the infarct size
was smaller in GK rats than in the control group. Systolic and diastolic functions were impaired in W + MI and did not reach
statistical significance in GK + MI animals compared to the corresponding controls. Among the 125 genes surveyed, 35 genes
showed a significant change in expression in GK + MI compared to W + MI rats. Short-term diabetes promotes compensatory
mechanisms that may provide cardioprotection against ischemia/reperfusion injury, at least in part, by increased antioxidants and
the upregulation of the prosurvival PI3K/Akt pathway, by the downregulation of apoptotic genes, proinflammatory cytokine TNF-
𝛼, profibrogenic TGF-𝛽, and hypertrophic marker 𝛼-actin-1.
1. Introduction
Diabetes mellitus (DM) is a common, chronic, metabolic
syndrome characterized by hyperglycemia, resulting from
defects in insulin secretion, insulin effects, or both. Type 2
diabetes accounts for more than 90% of all cases and is often
associatedwith hyperinsulinaemia, hyperglycaemia, and dys-
lipidaemia. DM can affect the cardiac structure and function
in the absence of hypertension, coronary artery disease, or
hyperlipidemia, a phenomenon known as diabetic cardiomy-
opathy. Diabetic cardiomyopathy is characterized by ventric-
ular dilatation, myocyte hypertrophy, prominent interstitial
fibrosis, and decreased or sustained systolic function [1] in
the presence of a diastolic dysfunction [2]. However, DM
not only affects the myocardium, but also leads to vascu-
lar complications. Macrovascular complications of DM are
responsible for the high incidence of vascular diseases, such
as myocardial infarction, which is caused by an imbalance
between the coronary blood flow and the metabolic demand
of the myocardium. Clinical studies have shown that patients
with DM are at a greater risk for myocardial infarction
and that, after an infarction, diabetes increases the risk for
the development of left-ventricular dysfunction and heart
failure when compared with nondiabetic individuals [3, 4].
Additionally, morbidity and mortality rates after myocardial
infarction are significantly higher in diabetic patients than
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in nondiabetic patients [5]. Myocardial infarct size is a
primary determinant of the prognosis in patients with acute
myocardial infarction. Although clinical studies showed
that DM increased the susceptibility of the myocardium to
ischemia/reperfusion injury [6, 7], infarct size studies in
diabetic animal models showed quite contradictory results,
especially at the early stage of the disease. It appears that the
susceptibility of the postischemic myocardial injury of the
diabetic heart is dependent on the duration of ischemia, the
duration and the stage of the diabetes, and/or the metabolic
profile. Evidence suggests that the ischemic hearts from the
mildly diabetic animals are resistant to ischemia [8], and the
severely diabetic hearts are more prone to ischemic injury
[9]. Several mechanisms have been proposed to explain the
cardioprotective property of a high glucose exposure, by an
increase in survival pathways, such as antiapoptotic factor
Bcl-2, and prosurvival factors such as protein kinase B (Akt),
the inactivation of the proapoptotic factor bad, inappropriate
expression of proangiogenic vascular endothelial growth
factor (VEGF), hypoxia inducible factor 1𝛼, and protein
kinase C-𝜀 [10].
The Goto-Kakizaki (GK) rat, a model of type 2 diabetes,
was developed from a stock of Wistar rats, by selective
breeding over many generations of rats with the highest
blood glucose levels during an oral glucose tolerance test [11].
GK rats develop mild hyperglycemia and hyperinsulinemia
and are not associated with the development of obesity,
hypertension, or hyperlipidemia. The spontaneous diabetic
GK rat thus offers a convenient model for studying the
pathogenesis of diabetic cardiomyopathy, independent from
the effect of hyperlipidemia, obesity, or hypertension.
Taking this into consideration, and in order to provide
further insight into the understanding of the myocardial cel-
lular/molecular events associated with short-term diabetes-
induced cardioprotection, we investigated the effects of a
myocardial ischemia/reperfusion injury on metabolic and
functional changes and on cardiac gene expression patterns
in GK rats. To that end, we evaluated in vivo the left-
ventricular mechanical function with a Millar pressure-
volume conductance catheter system, assessed biochemical
and histopathological changes, and identified changes in
myocardial gene expression relevant to diabetes, apoptosis,
oxidative stress, PI3K/Akt signalling, inflammation, cardiac
fibrosis, and hypertrophy using an RT2 Profiler PCR Arrays
system.
2. Materials and Methods
2.1. Animals. Spontaneously diabetic male GK rats (Taconic,
Ry, Denmark) and age-matched nondiabetic male Wistar
(W) control rats (Charles River, Sulzfeld, Germany) were
purchased at 4–9 weeks of age and studied at the age of 16
weeks. The animals were housed at a constant room temper-
ature (22 ± 2∘C) and 12 h light/dark cycles with free access
to standard laboratory rat diet and water. The investigation
conforms with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH) (publication no. 85-23, revised in 1996) and German
animal protection code. All procedures with and handling
of the animals during the investigations were reviewed and
approved by the appropriate institutional review board (G-
122/11).
2.2. Experimental Induction ofMyocardial Infarction. Therats
were anesthetized with a mixture of ketamine (100mg/kg)
and xylazine (3mg/kg) intraperitoneally. An intratracheal
tube was inserted, and the animals were artificially ventilated
using a rodent ventilator (Fo¨hr Medical Instruments GmbH,
Seeheim, Ober-Beerbach, Germany). The core temperature
(measured via a rectal probe) was maintained at 37∘C with
a controlled heating pad. The chest was opened via a left
thoracotomy, followed by a pericardiotomy. A 6-0 single silk
suture was passed around the left anterior descending (LAD)
coronary artery, and the ends of the tie were pulled through
a small pledget to form a snare and then tightened. After 45
minutes of ischemia, reperfusion was achieved by releasing
the snare. After surgery the thorax was closed, the skin was
sutured, and the ratswere allowed to recover on a heating pad.
Sham-operated animals were subjected to the same surgical
procedures, except that the suture under the LAD coronary
artery was not tied.
2.3. Experimental Groups. The rats were randomly divided
into four groups: (1) W + sham: sham-operated nondiabetic
Wistar control rats (𝑛 = 10); (2) GK + sham: sham-operated
diabetic GK animals (𝑛 = 7); (3) W + MI: myocardial
infarcted nondiabetic Wistar control rats (𝑛 = 9); (4) GK +
MI: myocardial infarcted diabetic GK animals (𝑛 = 8).
2.4. In Vivo Hemodynamic Measurements and Cardiac Func-
tion. Twenty-four hours after the reperfusion, the animals
were tracheotomised, intubated, and artificially ventilated.
A polyethylene catheter was inserted into the left external
jugular vein for fluid administration. A 2Fmicrotip pressure-
volume catheter was inserted into the right carotid artery and
advanced into the ascending aorta. After being stabilized for
5 minutes, the arterial blood pressure was recorded and the
catheter was advanced into the left-ventricle under pressure
control. With the use of a special pressure-volume analysis
program (PVAN, Millar Instruments, Houston, TX, USA),
heart rate, systolic blood pressure, diastolic blood pressure,
mean arterial pressure, ejection fraction,maximal slope of the
systolic pressure increment (𝑑𝑃/𝑑𝑡max), andmaximal slope of
the diastolic pressure decrement (𝑑𝑃/𝑑𝑡min) were computed
and calculated. The ventricular relaxation was assessed by
the time constant of left-ventricular pressure decay (Tau). It
was calculated by the Glantz method (Tau-g; regression of
𝑑𝑃/𝑑𝑡 versus pressure). The left-ventricular pressure-volume
relations are assessed by transiently compressing the inferior
vena cava. The slope 𝐸max of the left-ventricular end-systolic
pressure-volume relationship (ESPVR) was calculated as
a load-independent index of LV contractility. At the end
of each experiment, 0.1mL of hypertonic saline (5%) was
injected using the central venous line, and using the shift of
pressure-volume relations, the parallel conductance volume
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was calculated by the software and used for the correction of
the cardiac mass volume.
2.5. Biochemical Estimation. After 24 hours reperfusion had
been established, the heart functionwasmeasured, and blood
was collected from the abdominal aorta in Lithium-Heparin-
GelMonovette, EDTA, and serum tubes. After centrifugation,
the plasma and serum samples were obtained. Plasma glucose
levels, triglycerides, cholesterol, serum insulin levels, and
urinary glucose levels were determined by the usage of an
automatic biochemistry analyzer.
2.6. Histopathological Process. After the blood samples were
collected, pieces of the left-ventricularmyocardial tissue were
collected for histopathology, fixed in buffered paraformalde-
hyde solution (4%), and embedded in paraffin. Then, 5 𝜇m
thick sections were placed on adhesive slides and stained
with hematoxylin and eosin (H&E). Cardiomyocyte cross-
sectional areas were calculated under a microscope using the
Cell∧A software (Olympus Soft Imaging Solutions GmbH,
Germany). Masson’s trichrome staining was performed to
determine the extent of fibrosis. Four sections per heart
were inspected under light microscopy and rated according
to the following scoring system: grade 0 indicates normal
tissue showing no fibrotic region, grade 1 indicates mild
fibrosis, grade 2 indicates moderate fibrosis, and in grade
3 severe fibrosis is indicated. The histological evaluation
was conducted by an investigator unaware of the treatment
attribution of the animals.
2.7. Gene Expression Analysis Using RT2 Profiler PCR Arrays.
After the blood samples were collected, pieces of the left-
ventricular myocardial tissue were rapidly excised, frozen
in liquid nitrogen, and stored at −80∘C. The total RNA
was extracted from the hearts with miRNeasy Mini Kit
(Qiagen, Hilden, Germany) and was reverse-transcribed into
cDNA using the RT2 First Strand Kit, mixed with RT2
qPCR Master Mix containing SYBR Green according to
manufacturer’s instructions (Qiagen, Hilden, Germany). The
data was analyzed with the RT2 Profiler PCR Array Data
Analysis Template available on the manufacturer’s website.
2.8. Determination of Area at Risk and Infarct Size. After 24
hours reperfusion had been established, the heart function
was measured, and blood samples were collected. After
the heart was excised, a second investigator, unware of
the randomization, determined the infarct size. The hearts
were excised, quickly hung on a Langendorff apparatus, and
perfused with 0.9% NaCl solution in order to wash the blood
out from the coronary vessels. Then, the coronary artery
was religated with the help of the 6-0 single silk suture
previously located under the LAD coronary artery. Some
additional rats in each experimental group (𝑛 = 3/group)
were injected with 1.5mL of Evans blue dye (1% w/v) via
the aorta and coronary arteries to demarcate the ischemic
risk (nonstained) or nonrisk (stained) area of the heart.
The rest solely underwent 2,3,5-triphenyltetrazoliumchloride
(TTC) staining. The transverse heart tissue sections were
incubated with 1% TTC for 30 minutes at 37∘C. The viable
myocardium was stained with brick red due to the formation
of a precipitate that resulted from a reaction of TTC with
dehydrogenase enzymes. The loss of these enzymes from
the infarcted myocardium prevents the formation of the
precipitate, and the infarcted area within the region at risk
remains pale yellow. The tissue samples were then fixated
in 4% formalin solution for at least 24 hours. The mean
value of risk area has been calculated and used to determine
the infarct size of the area at risk of infarction. Individual
slices were photographed in colour using the Cell∧A software
(Olympus Soft Imaging Solutions GmbH, Germany), and
the extent of myocardial necrosis and the area at risk were
quantified.
2.9. Chemical Reagents. Sodium pentobarbital was pur-
chased from Merial GmbH (Hallbergmoos, Germany), and
Evans blue and TTCwere bought from Sigma-Aldrich (Stein-
heim, Germany).
2.10. Statistical Analysis. All data is expressed as mean ±
standard error of the mean (SEM). In case of the PCR
array gene expression, the 𝑃 values were calculated based on
Student’s 𝑡-test of the replicate 2−ΔCt values for each gene in
the experimental groups. Genes corresponding to a 𝑃 value
less than 0.05 are indicated in Table 4. In all other cases,
intergroup comparisons were performed by using a one-way
analysis of the variance, followed by Student’s unpaired 𝑡-
test with Bonferroni’s correction for multiple comparisons. A
value of 𝑃 < 0.05 was considered statistically significant.
3. Results
3.1. Biochemical Parameters. The biochemical values are
listed in Table 1. The plasma glucose levels were significantly
higher in diabetic rats compared to nondiabetic animals (GK
+ sham: 12.8 ± 1.5mM versus W + sham: 8.5 ± 0.4mM,
𝑃 < 0.05), indicating the manifestation of an overt diabetes.
Additionally, diabetic rats with myocardial infarction had
significantly higher glucose levels when compared with the
GK + sham animals (GK + MI: 19.0 ± 2.3mM versus GK
+ sham: 12.8 ± 1.5mM, 𝑃 < 0.05). High levels of urinary
glucose have been observed in diabetic rats compared to
the nondiabetic animals (Table 1). We found no difference
in the plasma cholesterol, triglyceride, and serum insulin
concentrations amongst the experimental groups.
3.2. Myocardial Infarct Size. In rats, subjected to coronary
artery occlusion and reperfusion, there was no difference in
the area at risk between the nondiabetic Wistar and diabetic
GK rats, indicating that a comparable degree of ischemic area
was induced (Wistar 47 ± 8% versus GK 42 ± 2%, 𝑃 = 0.42).
However, the myocardial infarct size (infarct zone/area at
risk) was smaller in diabetic hearts than in nondiabetic hearts
(GK + MI: 27 ± 6% versus W +MI: 53 ± 9%, 𝑃 < 0.05).
3.3. Myocardial Hypertrophy and Fibrotic Remodelling. Com-
pared to the corresponding age-matched control rats, the
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Table 1: Biochemical parameters in Goto-Kakizaki (GK) and control rats 24 h after sham operation or myocardial infarction.
W + sham GK + sham W +MI GK + MI
Plasma glucose [mmol/L] 8.5 ± 0.4 12.8 ± 1.5∗ 8.4 ± 0.6 19.2 ± 2.3∗#$
Plasma triglycerides [mg/dL] 67 ± 9 60 ± 9 67 ± 7 88 ± 8
Plasma cholesterol [mg/dL] 70 ± 8 93 ± 6 71 ± 7 91 ± 7
Serum insulin [mU/L] 6.3 ± 0.8 5.3 ± 0.2 5.4 ± 0.5 5.1 ± 0.6
Urine glucose [g/L] 0.13 ± 0.02 0.73 ± 0.28∗$ 0.14 ± 0.03 0.76 ± 0.15∗$
Data is expressed as mean ± SEM; ∗𝑃 < 0.05 versus W + sham; #𝑃 < 0.05 versus GK + sham; $𝑃 < 0.05 versus W + MI; MI indicates myocardial infarction;
GK: Goto-Kakizaki; W: Wistar.
Table 2: Physiological characteristics of Goto-Kakizaki (GK) and control rats 24 h after sham operation or myocardial infarction.
W + sham GK + sham W +MI GK + MI
Body weight [g] 450 ± 6 331 ± 8∗$ 444 ± 11 322 ± 6∗$
Heart weight to body weight ratio [×1,000] 2.96 ± 0.08 3.73 ± 0.10∗ 3.54 ± 0.10∗ 4.05 ± 0.09∗$
Heart rate [beats/min] 453 ± 13 454 ± 28 456 ± 6 453 ± 4
SBP [mmHg] 145 ± 6 123 ± 6 137 ± 8 120 ± 7∗
DBP [mmHg] 117 ± 5 89 ± 6∗ 113 ± 8 92 ± 8∗
MAP [mmHg] 126 ± 5 100 ± 6∗ 121 ± 8 102 ± 7∗
Data is expressed as mean ± SEM; ∗𝑃 < 0.05 versus W + sham; $𝑃 < 0.05 versus W +MI; MI indicates myocardial infarction; GK: Goto-Kakizaki; W: Wistar;
SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure.
body weight was significantly lower, and the heart-to-body
weight ratio was higher in diabetic animals (Table 2). Fur-
thermore, the histological examination revealed that the
cardiomyocyte transverse cross-sectional area in the GK +
sham and GK + MI rats was significantly increased in the
H&E-stained sections compared to the nondiabetic animals
(Figure 1). Additionally, Masson’s trichrome stained sections
showed myocardial fibrosis in GK + sham and GK + MI rats
compared to the nondiabetic animals (Figure 2).
3.4. Cardiac Pump Function. The heart rate did not differ
between the experimental groups (Table 2). The systolic
blood pressure in GK + MI animals and the diastolic blood
pressure and mean arterial pressure in GK + sham and
GK + MI rats were significantly lower compared to the W
+ sham animals (Table 2). The cardiac index derived from
a pressure-volume analysis is shown in Figure 3. Although
the induction of acute myocardial infarction in nondiabetic
rats significantly decreased systolic performance (ejection
fraction, 𝑑𝑃/𝑑𝑡max) and ventricular relaxation (𝑑𝑃/𝑑𝑡min,
Tau-g), it had no effect on diabetic rats when compared to
the corresponding control groups (Figure 3).
3.5. Myocardial Gene Expression Analysis Using RT2 Profiler
PCR Arrays. The significantly upregulated and downregu-
lated 125 genes surveyed are shown in Tables 3 and 4 and
in Figure 4. DM only significantly altered the expression
of 5 genes (2 upregulated and 3 downregulated) in the
hearts of GK + sham animals compared to W + sham rats.
Only 4 genes (2 upregulated and 2 downregulated) showed
significant expression changes in the hearts of GK + MI
animals compared to GK + sham rats. However, 35 genes
(19 upregulated and 16 downregulated) showed significant
changes in expression in the hearts of GK + MI animals
compared to W + MI rats. Genes whose expression was
found to be highly up- and downregulated (fold change >
+/−3) were mostly related to the onset, development, and
progression of diabetes [glycerol-3-phosphate dehydrogenase
(Gpd)-1, insulin-like growth factor binding protein (Igfbp)-
5, phosphorylase glycogen liver (Pygl), heme oxygenase
(Hmox)-1], apoptosis [cell death-inducing DFFA-like effec-
tor (Cidea)], antioxidants [superoxidase dismutase (Sod)-3,
catalase], PI3K/Akt signaling pathway [pyruvate dehydroge-
nase kinase, isozyme (Pdk)-2, ribosomal protein S6 kinase
polypeptide (Rps6ka)-l], cardiac fibrosis [matrix metallopep-
tidase (Mmp)-2, Gremlin-1], inflammation [tumor necrosis
factor (Tnf)], and hypertrophy [myosin, light polypeptide
(Myl)-2]. Acute myocardial infarction in nondiabetic rats (W
+MI) altered 50 genes (19 upregulated and 16 downregulated)
in comparison to the W + sham rats. These genes (fold
change > +/−3) weremostly related to the PI3K/Akt signaling
pathway [Rps6ka-l, bruton agammaglobulinemia tyrosine
kinase (btk), Pdk-1, Pdk-2], inflammation [interleukin (Il)1b,
Il6, Tnf], cardiac fibrosis [transforming growth factor (Tgf)-
beta, Mmp2], hypertrophy [natriuretic peptide precursor
A (Nppa), alpha actin (Acta)-1, FBJ osteosarcoma onco-
gene (Fos), Myl-2], ischemia/reperfusion injury [Hmox1],
apoptosis [Cidea], and antioxidants [glutathione peroxydase
(Gpx)-4, glutathione S-transferase kappa (Gstk)-1, thiore-
doxin reductase (Txnrd)2, sod3, catalase]. Additionally, the
mRNAexpressions of 4 genes corresponding to sod3, Il6, Il1b,
and ctgf were highly regulated in W + MI compared to W +
sham hearts, showing more than 11-fold change (fold changes
for sod3: −14.7, Il6: +13.6, Il1b: +12.9, and ctgf: +12.0).
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Figure 1: Histological analysis (hematoxylin and eosin staining). (a) Hematoxylin and eosin staining micrographs of transverse sections of
myocardium (magnification ×400, scale bar: 50 𝜇m) and (b) quantitative analysis of cardiomyocyte cross-sectional area using measurements
of ∼20 cardiomyocytes in each group. Data is presented as mean ± SEM. ∗𝑃 < 0.05 versus W; GK; $𝑃 < 0.05 versus W + MI. MI indicates
myocardial infarction; GK: Goto-Kakizaki; W: Wistar.
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Figure 2: Histological analysis (Masson’s trichrome staining). Histological examination of the myocardium stained with Masson’s trichrome
(magnification ×100, scale bar: 100 𝜇m). Data is presented as mean ± SEM. ∗𝑃 < 0.05 versus W; #𝑃 < 0.05 versus GK; $𝑃 < 0.05 versus W +
MI.MI indicates myocardial infarction; GK: Goto-Kakizaki;W:Wistar. Masson’s trichrome staining (grade 0 indicates normal tissue showing
no fibrotic region; grade 1 indicates mild fibrosis; grade 2 indicates moderate fibrosis, and grade 3 indicates severe fibrosis).
4. Discussion
The aim of this study was to investigate additional molecular
pathomechanisms of acute myocardial infarction in mildly
diabetic GK rats. In line with the previous literature [8, 12, 13],
our results showed that DM decreases myocardial suscepti-
bility to ischemia/reperfusion injury. We demonstrated that
this short-term and mild diabetes-induced cardioprotection
may be, at least in part, due to an increased transcriptional
expression of markers of antioxidant defense and the prosur-
vival PI3K/Akt pathway and due to the downregulation of
apoptotic genes, proinflammatory cytokine tumor necrosis
factor-𝛼, profibrogenic transforming growth factor-𝛽, and
hypertrophic marker alpha actin-1. This present work addi-
tionally expands previous studies by identifying additional
target genes associated with the cardioprotective effect of
middle diabetes against ischemia/reperfusion injury.
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Figure 3: Left-ventricular systolic and diastolic function. Assessment of (a) ejection fraction, (b) maximal slope of the systolic pressure
increment 𝑑𝑃/𝑑𝑡max, (c) maximal slope of the diastolic pressure decrement 𝑑𝑃/𝑑𝑡min, and (d) time constant of left-ventricular pressure decay
Tau-g. Data is expressed as mean ± SEM. ∗𝑃 < 0.05 versus W + sham. MI indicates myocardial infarction; GK: Goto-Kakizaki; W: Wistar.
Diabetic cardiomyopathy, an early complication of dia-
betes, is a result of complex interactions between metabolic
abnormalities (hyperinsulinemia, hyperlipidemia, and hyp-
erglycemia) that accompany diabetes and their cellular
consequences (oxidative stress, endothelial dysfunction,
inflammation, and renin angiotensin aldosterone system
activation), resulting in functional (systolic and diastolic
dysfunction) and structural (left-ventricular hypertrophy
and cardiac fibrosis) changes in the myocardium. In the
present study, higher plasma and urine glucose levels,
cardiomyocyte hypertrophy, and myocardial fibrosis were
documented and the cardiac function was indistinguishable
in GK rats when compared with nondiabetic animals.
Despite these impairments, DM significantly altered only
5 of the tested genes involved in cardiac fibrosis (ctgf),
hypertrophy (Nppa), and inflammation (Tnf, Il1b, Crp).
Although clinical trials showed that DM increased the
sensitivity of the myocardium to ischemia/reperfusion injury
[6, 7], infarct size studies in diabetic animal models have
produced variable results. Some studies have shown that the
diabetic heart is more sensitive to ischemic injury [14–16];
others found no difference [17, 18]. It has been also demon-
strated that the myocardium of animals with DM compared
to nondiabetic animals paradoxically is more resistant to
ischemia, resulting in smaller myocardial infarctions [8, 12].
The reasons for the disparity between the animal and clinical
data were the subject of a review in 1997, by Paulson, who
concluded that the sensitivity of the diabetic heart to acute
myocardial ischemia/reperfusion injury was dependent on
the animal models and conditions used [9]. Additionally, in
2012, Whittington et al. added another complicating factor,
the choice of the ischemia/reperfusion injury model, and
the lack of other comorbidities such as age, dyslipidemia,
and hypertension [19]. The duration and severity of the
diabetic state, ischemic insults, and metabolic profiles after
Journal of Diabetes Research 7
Table 3: Genes Table.
Official full name Genesymbol Official full name
Gene
symbol
Acyl-coenzyme A dehydrogenase, short/branched
chain Acadsb Interleukin 10 Il10
ATP citrate lyase Acly Interleukin 1 beta Il1b
Actin, alpha 1, skeletal muscle Acta1 Interleukin 6 Il6
Bcl2-associated X protein Bax Insulin receptor substrate 1 Irs1
Bruton agammaglobulinemia tyrosine kinase Btk Insulin receptor substrate 2 Irs2
Caspase 3 Casp3 Matrix metallopeptidase 2 Mmp2
Catalase Cat Myosin, light polypeptide 2, regulatory, cardiac, slow Myl2
Chemokine (C-C motif) ligand 11 Ccl11 Natriuretic peptide precursor A Nppa
Cell death-inducing DFFA-like effector a Cidea Pyruvate dehydrogenase kinase, isozyme 1 Pdk1
Cell death-inducing DFFA-like effector b Cideb Pyruvate dehydrogenase kinase, isozyme 2 Pdk2
C-reactive protein, pentraxin-related Crp Phosphoinositide-3-kinase, catalytic, delta polypeptide Pik3cd
Connective tissue growth factor Ctgf Phosphoinositide-3-kinase, catalytic, gamma polypeptide Pik3cg
Dipeptidylpeptidase 4 Dpp4 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha) Pik3r1
Ectonucleotide
pyrophosphatase/phosphodiesterase 1 Enpp1 Protein kinase C, beta Prkcb
FBJ osteosarcoma oncogene Fos Protein kinase C, zeta Prkcz
Glucokinase Gck Protein tyrosine phosphatase, nonreceptor type 1 Ptpn1
Glycerol-3-phosphate dehydrogenase 1 (soluble) Gpd1 Phosphorylase, glycogen, liver Pygl
Glutathione peroxidase 3 Gpx3 Ribosomal protein S6 kinase polypeptide 1 Rps6ka1
Glutathione peroxidase 4 Gpx4 Superoxide dismutase 1, soluble Sod1
Growth factor receptor bound protein 10 Grb10 Superoxide dismutase 2, mitochondrial Sod2
Gremlin 1, cysteine knot superfamily,
homolog (xenopus laevis) Grem1 Superoxide dismutase 3, extracellular Sod3
Glutathione reductase Gsr Sulfiredoxin 1 homolog (S. cerevisiae) Srxn1
Glutathione S-transferase kappa 1 Gstk1 Transforming growth factor, beta 1 Tgfb1
Glutathione S-transferase pi 1 Gstp1 Tumor necrosis factor (TNF superfamily, member 2) Tnf
Heme oxygenase (decycling) 1 Hmox1 Tumor protein p53 Tp53
Heat shock protein 1 Hspb1 Tribbles homolog 3 (Drosophila) Trib3
Interferon gamma Ifng Thioredoxin reductase 2 Txnrd2
Insulin-like growth factor binding protein 5 Igfbp5
the diabetic induction play a role in explaining the vulnera-
bility of diabetic hearts to myocardial ischemia/reperfusion
injury. One of the reasons for the increased myocardial
ischemic tolerance in diabetic animals may be associated
with hypotension and bradycardia [20]. At the same time,
different authors supported the endogenous cardioprotective
phenotype (metabolic preconditioning) of the myocardium
in the absence of differences in the hemodynamic mea-
surements between control and diabetic animals [12]. In
the present work, to evaluate the cardiac function, different
indices were calculated. Our results showed that even though
acute myocardial infarction decreased 𝑑𝑃/𝑑𝑡max (an index
of contractility) and ejection fraction (widely used clinical
parameter of systolic performance) in nondiabetic rats, it
had no effects on diabetic animals. Additionally, the left-
ventricular diastolic function, evaluated by𝑑𝑃/𝑑𝑡min andTau,
has shown to be impaired by acute myocardial infarction
in nondiabetic rats, while it was not significantly impaired
in diabetic animals. However, we documented a modest
hypotension in diabetic rats. Altogether, our results demon-
strated that in the absence of differences in the cardiac systolic
and diastolic functions, the infarct sizewas smaller in diabetic
animals than in nondiabetic rats. However, the induction
of a myocardial infarction in diabetic animals increased the
glucose levels further when compared to the sham-operated
diabetic animals. Furthermore, in the ischemic/reperfused
diabetic myocardium only 2 of the tested genes were upreg-
ulated and 2 downregulated, when compared to diabetic
hearts. This data suggests that an acute myocardial infarction
in mild diabetic animals did not induce additional cardiac
damage when compared to the noninfarcted diabetic rats.
Although the persistence of a hyperglycaemic environ-
ment prior to the ischemia/reperfusion injury may induce a
myocardial adaptation [13], the exact mechanisms need to be
elucidated. The following mechanisms have been proposed
to explain the lower sensitivity of the acutely diabetic hearts
8 Journal of Diabetes Research
Table 4: Significant upregulated and downregulated genes in Goto-Kakizaki (GK) and control rats 24 h after sham operation or myocardial
infarction. MI indicates myocardial infarction; W: Wistar.
Functional groups Genes GK + sham fold change versus W + sham 𝑃 value
Cardiac fibrosis Ctgf +3.707 0.001532
Hypertrophy Nppa +6.2756 0.016233
Inflammation Il1b −3.1518 0.011374
Inflammation Tnf −3.1183 0.016066
Inflammation Crp −2.0963 0.035534
Functional groups Genes GK + MI fold change versus GK + sham 𝑃 value
Diabetes Tnf +5.6225 0.035036
Diabetes Pygl +3.1994 0.020738
Oxidative stress Gstp1 −2.0236 0.021563
Cardiac fibrosis Ccl11 −2.9549 0.035774
Functional groups Genes GK + MI fold change versus W +MI 𝑃 value
Diabetes Gpd1 +6.641 0.001417
Diabetes Igfbp5 +5.8232 0.01159
Diabetes Ifng +2.9216 0.005641
Diabetes Irs1 +2.7073 0.028661
Diabetes Irs2 +2.5629 0.026471
Apoptosis Cidea +6.8588 0.020129
Antioxidant Sod3 +8.4477 0.017228
Antioxidant Cat +3.6086 0.013688
Antioxidant Gstk1 +2.9415 0.013792
Antioxidant Gpx3 +2.5874 0.005335
Antioxidant Gpx4 +2.2143 0.008235
Antioxidant Txnrd2 +2.4704 0.015564
Oxidative stress Acadsb +2.4938 0.008752
PI3K-AKT Pdk2 +4.0001 0.01737
PI3K-AKT Irs1 +2.7073 0.028661
PI3K-AKT Prkcz +2.4657 0.012351
PI3K-AKT Pdk1 +2.4067 0.039144
Cardiac fibrosis Mmp2 +4.4052 0.005183
Hypertrophy Myl2 +4.069 0.004222
Diabetes Hmox1 −3.3902 0.004516
Diabetes Pygl −3.0173 0.034296
Diabetes Enpp1 −2.4937 0.008265
Diabetes Tgfb1 −2.4518 0.001187
Diabetes Pik3cd −2.3951 0.005374
Apoptosis Tp53 −2.5259 0.011446
Apoptosis Casp3 −2.427 0.012582
Apoptosis Bax −2.1017 0.00374
PIK-AKT Rps6ka1 −3.4451 0.002956
PIK-AKT Pik3cg −2.9438 0.009444
PIK-AKT Btk −2.7497 0.035023
PIK-AKT Prkcb −2.1591 0.003529
Inflammation Tnf −4.427 0.003721
Cardiac fibrosis Grem1 −6.0096 0.040211
Cardiac fibrosis Ctgf −2.8267 0.039161
Hypertrophy Acta1 −2.485 0.001472
Functional groups Genes W +MI fold change versus W + sham 𝑃 value
Diabetes Pygl +6.0176 0.012007
Diabetes Pik3cd +3.6417 0.00072
Diabetes Trib3 +3.4219 0.021015
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Table 4: Continued.
Diabetes Enpp1 +2.8888 0.000436
Diabetes Acly +2.1769 0.000508
Diabetes Ptpn1 +2.1691 0.005677
Apoptosis Casp3 +2.8879 0.002393
Apoptosis Bax +2.5914 0.001228
Apoptosis Cideb +2.3322 0.000832
Apoptosis Tp53 +2.0869 0.007736
Oxidative stress Gsr +2.0059 0.013533
Antioxidants Srxn1 +2.4303 0.002489
PIK-AKT Btk +5.0358 0.009847
PIK-AKT Rps6ka1 +4.6552 0.000443
PIK-AKT Pik3cg +2.9829 0.00643
PIK-AKT Hspb1 +2.2659 0.020669
PIK-AKT Prkcb +2.1022 0.005081
Inflammation Il6 +13.5898 0.009511
Inflammation Il1b +12.9385 0.027718
Inflammation Tnf +8.1656 0.000652
Inflammation Il10 +2.814 0.027362
Cardiac fibrosis Ctgf +11.9928 0.000743
Cardiac fibrosis Tgfb1 +3.647 0.000073
Hypertrophy Nppa +5.1685 0.02716
Hypertrophy Acta1 +3.5345 0.000146
Hypertrophy Fos +3.3651 0.043876
Ischemia/reperfusion injury Hmox1 +4.1327 0.004281
Diabetes Gpd1 −8.3354 0.000051
Diabetes Irs1 −4.025 0.008703
Diabetes Igfbp5 −3.7655 0.0052
Diabetes Ifng −3.2748 0.016763
Diabetes Gck −3.1419 0.046149
Diabetes Dpp4 −2.4258 0.019147
Apoptosis Cidea −6.5517 0.000294
Antioxidant Sod3 −14.7384 0.000054
Antioxidant Gstk1 −4.9174 0.000258
Antioxidant Txnrd2 −3.3769 0.000067
Antioxidant Gpx4 −3.1555 0.000135
Antioxidant Gpx3 −2.9402 0.005985
Antioxidant Sod1 −2.1671 0.000249
Antioxidant Sod2 −2.0326 0.002173
Oxidative stress Acadsb −4.092 0.002653
Antioxidant Cat −4.6839 0.000134
PI3K-AKT Pdk2 −6.0865 0.000008
PI3K-AKT Pdk1 −4.2831 0.000002
PI3K-AKT Pik3r1 −2.8108 0.009969
PI3K-AKT Grb10 −2.4946 0.000153
PI3K-AKT Prkcz −2.3207 0.039517
Cardiac fibrosis Mmp2 −5.9891 0.000011
Hypertrophy Myl2 −4.5332 0.000579
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Figure 4: PCR array gene expression clustergrams: (a) GK + sham versus W + sham, (b) GK +MI versus GK + sham, (c) GK +MI versus W
+MI, and (d) W +MI versus W + sham. MI indicates myocardial infarction; GK: Goto-Kakizaki; W: Wistar.
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to ischemia/reperfusion injury: the degree of intracellular
acidity and how the cells handle this acidosis [21]. It has
also been shown that preischemic myocardial glycogen
content is increased in diabetic hearts [22, 23], and high
glycogen reserves protect from ischemic damage resulting
in smaller infarcts in the diabetic rat hearts [22]. Short-
term diabetes may also increase the myocardial content of
free-radical scavenging enzymes, catalase, and glutathione
reductase which may also be involved [24, 25]. In the present
study, we evaluated the effects of mild hyperglycemia after
acutemyocardial infarction on the ventricular transcriptional
profile, using quantitative gene approaches. In line with
these observations, our RT2 Profiler PCR Array results
confirmed that reductions in the myocardial infarct area may
be, at least in part, due to the upregulation of antioxidant
enzymes including glutathione peroxidase-3 and peroxidase-
4, glutathione S-transferase kappa-1, thioredoxin reductase-2,
superoxide dismutase-3, and catalase.
Insulin sequentially activates the insulin receptor, PI3K,
and Akt [26] through phosphorylation at threonine 308 and
serine 473 [27]. Insulin receptor substrates- (Irs-) 1 and Irs-2
have been shown to play major roles in the control of cardiac
homeostasis, metabolism, and function. Suppressing cardiac
IRS-1 and IRS-2 may serve as a fundamental mechanism for
induction of heart failure [28]. A growing body of evidence
indicates that the PI3K/Akt pathway is generally considered
to be beneficial for heart function [29]. The abnormal
regulation of the PI3K/Akt pathway may be one of several
factors contributing to diabetes-induced cardiac dysfunction,
and its activationmay prevent cardiac myocyte apoptosis and
protect the myocardium from ischemia/reperfusion injury
in vivo [30]. In the present work, we studied the prosur-
vival PI3K/Akt signal transduction pathway. An increased
mRNA expression of Irs-1, Prkcz (a downstream of IRS-
1 and PI3K), pyruvate dehydrogenase kinase (Pdk)-1, and
Pdk-2 was observed in diabetic rats after myocardial infarc-
tion. Elevated inflammatory mediators have been shown
to reduce the phosphorylation of tyrosine in IRS-1 and to
reduce the activation of the PI3K/Akt pathway [31]. In line
with these observations, genes encoding proteins, including
markers of proinflammatory cytokine tumor necrosis factor-
𝛼, were downregulated in the ischemic/reperfused diabetic
myocardium.
A programmed cell death mechanism or apoptosis plays
a major role in the pathogenesis of diabetic cardiomyopathy.
We showed that genes encoding proteins, including markers
of apoptosis (cidea, Tp53, Bax, and caspase 3), were down-
regulated in diabetic hearts after acute myocardial infarction.
Cardiac cell death can induce a compensatory hypertrophy
of myocardial cells and reparative fibrosis [32]. Our results
also showed that markers of myocardial fibrosis (Mmp-2,
ctgf, andGrem-1), cardiac hypertrophy (myl-2 and acta1), and
profibrogenic transforming growth factor-𝛽 were regulated
in diabetic hearts after myocardial infarction. These findings
provide new insight into the identification of potential genes
that may be involved in mild hyperglycaemia environment
induced protection against myocardial ischemia/reperfusion
injury.
In the present study, our results showed that nondi-
abetic hearts are more sensitive to ischemia/reperfusion
injury than the diabetic myocardium. Acute myocardial
infarction impaired systolic performance (as evidenced by
decreased 𝑑𝑃/𝑑𝑡max and ejection fraction) and ventricular
relaxation (as shown by decreased 𝑑𝑃/𝑑𝑡min and prolonged
Tau). The restoration of blood flow to the nondiabetic
ischemic myocardium can cause injury. Ischemic damage
and hypoxia induce the secretion of proinflammatory medi-
ators, such as reactive oxygen species (ROS), cytokines, and
chemokines, and cause ATP depletion. Furthermore, during
reperfusion, the acute ischemic myocardium is subjected to
several abrupt biochemical and metabolic changes including
intracellular calcium overload, energy depletion, acidosis,
activation of granulocytes, and the generation of reactive
oxygen species [33]. During the postmyocardial infarction
period, we showed that nondiabetic hearts responded with
altered levels for transcripts representing markers of inflam-
mation (upregulation of Il10, Tnf, Il1b, and Il6 expres-
sions), apoptosis (upregulation of Tp53, Bax, and caspase 3
expressions), antioxidant defense (downregulation of Gpx3,
Gpx4, Gstk1, Txnrd2, Sod3, and catalase expressions), and
the prosurvival PI3K/Akt pathway (upregulation of Rps6k,
Btk, Pik3cg, and Prkcb and down regulation of pdk2 and
Prkcz expressions). These genes were inversely regulated
in ischemic/reperfused diabetic hearts when compared to
the nondiabetic myocardium. Hence, it is plausible to
speculate that these genes may play an important role in
the short-term induced cardioprotection against myocardial
ischemia/reperfusion injury.
5. Conclusions
Our data shows that a mild hyperglycaemic environment
provides protection to the heart against ischemia/reperfusion
injury, at least in the early phase of the disease. Lists of
genes demonstrating changes in their expression patterns
are strongly influenced by the duration and severity of the
diabetic state and ischemic insults. In our setup (45min
ischemic time and 24 h reperfusion), the downregulation
of apoptotic genes, myocardial proinflammatory cytokine
tumor necrosis factor-𝛼, hypertrophic marker alpha actin-
1, and profibrogenic transforming growth factor-𝛽 may at
least be due to the activation of the prosurvival PI3K/Akt
pathway and the upregulation of antioxidants during the
acute phase of diabetes. From a clinical perspective, gene
expression profiling studies aiming towards the discovery of
pathways and identification of factors leading to coronary
heart disease in diabetic patients, a high risk population, may
help to design new preventive/therapeutic strategies.
A limitation of our study was that we did not investigate
the protein expression of the genes in PRC array that were
regulated but confined the investigation solely to profiling
the myocardial transcriptome in diabetic rats after acute
myocardial infarction.
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